A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme: Final Report (Protocol BT-21)

Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski

Burzynski Clinic, Houston, Texas, USA.

DOI: 10.4236/jct.2014.510100                

Abstract

Treatment of recurrent glioblastoma multiforme (RGBM) creates one of the most difficult challenges to neuro-oncology. The purpose of this study is to evaluate the outcome of adults with high-grade glioma with special attention to RGBM patients treated with Antineoplastons (ANP) A10 and AS2-1 injections. The study was conducted according to Protocol BT-21, which accrued patients who failed standard radiation therapy (RT) and chemotherapy. There were 40 candidates registered in the study. Among the intent-to-treat (ITT) population, there were 30 cases of RGBM that progressed during and after prior treatment, 4 patients with anaplastic astrocytoma (AA), 1 with anaplastic mixed glioma (AMG), and 5 with persistent GBM. The aim of this paper is to evaluate the responses, survival and toxicity of all 40 patients, the efficacy in 30 patients with RGBM, and in 24 patients with RGBM who received at least 28 days of ANP (ERGBM). All RGBM patients were treated before with RT and chemotherapy, except one patient who only had surgery (patient refused radiation). In this group, 63% had one recurrence, 30% had two recurrences, and 7% had three recurrences. The median duration of ANP and ITT was 12 weeks and the median dosage of ANP A10 was 6.52 g/kg/d and ANP AS2-1 was 0.23 g/kg/d. Responses were assessed by gadolinium-enhanced magnetic resonance imaging (MRI) repeated every eight weeks. In the ITT population, objective responses (ORs) were determined in 10% of cases (complete response—CR, and partial response—PR in 5% each). Progression-free survival (PFS) in ITT at six months was 17.5%. Overall survival (OS) was 28.3% at one year, 2.6% at two years, five and ten years. In the RGBM population, objective responses (ORs) were determined in 13.3% of cases (CR and PR in 6.7% each). PFS in RGBM at six months was 16.7%. OS was 34.7% at one year, 3.47% at two years, five and ten years. In the ERGBM population, ORs were determined in 16.7% of cases (CR and PR in 8.3% each). PFS in ERGBM at six months was 20.8%, OS was 39.3% at one year, 4.4% at two years, five and ten years. The treatment was well-tolerated with reversible Grades 3 and 4 toxicity in 17.5% of patients (7 patients who experienced multiple toxicities) and no chronic toxicity. In conclusion, the study reached efficacy endpoint. ANP is well-tolerated and compares favorably to the current treatment for RGBM.

Keywords

Antineoplastons A10 and AS2-1, Recurrent Glioblastoma Multiforme, Phase II Clinical Trial, Survival in Glioblastoma

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Ostrom, Q.T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., et al. (2013) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro-Oncology, 15, ii1-ii56. http://dx.doi.org/10.1093/neuonc/not151
[2]	Fisher, J.L., Schwartzbaum, J., Wrensch, M. and Wiemels, J.L. (2007) Epidemiology of Brain Tumors. Neurologic Clinics, 25, 867-890. http://dx.doi.org/10.1016/j.ncl.2007.07.002
[3]	Wrensch, M., Lee, M., Miike, R., et al. (1997) Familial and Personal Medical History of Cancer and Nervous System Conditions among Adults with Glioma and Controls. American Journal of Epidemiology, 145, 581-593. http://dx.doi.org/10.1093/oxfordjournals.aje.a009154
[4]	Preston, D.L., Ron, E., Yonehara, S., et al. (2002) Tumors of the Nervous System and Pituitary Gland Associated with Atomic Bomb Radiation Exposure. Journal of the National Cancer Institute, 94, 1555-1563. http://dx.doi.org/10.1093/jnci/94.20.1555
[5]	(1982) Brain Tumors in the Chemical Industry. Annals of the New York Academy of Sciences, 381, 1-362.
[6]	National Toxicology Program (1978) Bioassay of 1H-Benzotriazole for Possible Carcinogenicity. National Cancer Institute Carcinogenesis Technical Report Series, 88, 1-131.
[7]	Sills, R.C., Hailey, J.R., Neal, J., Boorman, G.A., Haseman, J.K. and Melnick, R.L. (1999) Examination of Low-Incidence Brain Tumor Responses in F344 Rats Following Chemical Exposures in National Toxicology Program Carcinogenicity Studies. Toxicologic Pathology, 27, 589-599. http://dx.doi.org/10.1177/019262339902700513
[8]	U.S. Department of Labor OSHA (2007) Occupational Safety and Health Guideline for Glycidol. Washington, D.C.
[9]	Turner, M.C., Chen, Y., Krewski, D. and Ghadirian, P. (2006) An Overview of the Association between Allergy and Cancer. International Journal of Cancer, 118, 3124-3132. http://dx.doi.org/10.1002/ijc.21752
[10]	Wrensch, M., Wiencke, J.K., Wiemels, J., et al. (2006) Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival. Cancer Research, 66, 4531-4541. http://dx.doi.org/10.1158/0008-5472.CAN-05-4032
[11]	Hanahan, D. and Weinberg, R.A. (2000) The Hallmarks of Cancer. Cell, 100, 57-70. http://dx.doi.org/10.1016/S0092-8674(00)81683-9
[12]	Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.A., Jones, D.T.W., Konermann, C., et al. (2012) Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 22, 425-437. http://dx.doi.org/10.1016/j.ccr.2012.08.024
[13]	Burzynski, S.R. and Patil, S.S. (2014) The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. Journal of Cancer Therapy, in press.
[14]	Burzynski, S.R., Burzynski, G.S. and Janicki, T.J. (2014) Recurrent Glioblastoma Multiforme, a Strategy for Long-Term Survival. Journal of Cancer Therapy, in press.
[15]	Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., et al. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 352, 987-996. http://dx.doi.org/10.1056/NEJMoa043330
[16]	Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., et al. (2005) MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine, 352, 997-1003. http://dx.doi.org/10.1056/NEJMoa043331
[17]	Gilbert, M.R., Wang, M., Aldape, K.D., Stupp, R., Hegi, M., Jaeckle, K.A., et al. (2011) RTOG 0525: A Randomized Phase III Trial Comparing Standard Adjuvant Temozolomide (TMZ) with a Dosedense (dd) Schedule in Newly Diagnosed Glioblastoma (GBM). Journal of Clinical Oncology, 29, 2006.
[18]	National Comprehensive Cancer Network. NCCN Guidelines: Central Nervous System Cancers. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
[19]	Weller, M., Cloughesy, T., Perry, J.R. and Wick, W. (2013) Standards of Care for Treatment of Recurrent Glioblastoma—Are We There Yet? Neuro-Oncology, 15, 4-27. http://dx.doi.org/10.1093/neuonc/nos273
[20]	Omuro, A., Chan, T.A., Abrey, L.E., Khasraw, M., Reiner, A.S., Kaley, T.J., et al. (2013) Phase II Trial of Continuous Low-Dose Temozolomide for Patients with Recurrent Malignant Glioma. Neuro-Oncology, 15, 242-250. http://dx.doi.org/10.1093/neuonc/nos295
[21]	Burzynski, S.R. (2004) The Present State of Antineoplaston Research (1). Integrative Cancer Therapies, 3, 47-58. http://dx.doi.org/10.1177/1534735403261964
[22]	Burzynski, S.R., Conde, A.B., Peters, A., Saling, B., Ellithorpe, R., Dougherty, J.P. and Nacht, C.H. (1999) A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumours. Clinical Drug Investigation, 18, 1-10. http://dx.doi.org/10.2165/00044011-199918010-00001
[23]	Wen, P.Y., Macdonald, D.R., Reardon, D.A., Cloughesy, T.F., Sorensen, A.G., Galanis, E., et al. (2010) Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 28, 1963-1972. http://dx.doi.org/10.1200/JCO.2009.26.3541
[24]	Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Spence, A.M., Berger, M.S., Mehta, M.P., Bozik, M.E., Pollack, I., Schiff, D., Gilbert, M., Rankin, C. and Prados, M.D. (1999) Phase II Study of Phenylacetate in Patients with Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. Journal of Clinical Oncology, 17, 984-990.
[25]	Vredenburgh, J.J., Desjardins, A., Herndon, J.E., Dowell, J.M., Reardon, D.A., Quinn, J.A., et al. (2007) Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. Clinical Cancer Research, 13, 1253-1259. http://dx.doi.org/10.1158/1078-0432.CCR-06-2309
[26]	Reardon, D.A., Desjardins, A., Peters, K.B., Vredenburgh, J.J., Gururangan, S., Sampson, J.H., McLendon, R.E., Herndon II, J.E., Coan, A., Threatt, S., Friedman, A.H. and Friedman, H.S. (2011) Phase 2 Study of Carboplatin, Irinotecan, and Bevacizumab for Recurrent Glioblastoma after Progression on Bevacizumab Therapy. Cancer, 117, 5351-5358. http://dx.doi.org/10.1002/cncr.26188
[27]	Desjardins, A., Reardon, D.A., Coan, A., Marcello, J., Herndon II, J.E., Bailey, L., Peters, K.B., Friedman, H.S. and Vredenburgh, J.J. (2012) Bevacizumab and Daily Temozolomide for Recurrent Glioblastoma. Cancer, 118, 1302-1312. http://dx.doi.org/10.1002/cncr.26381